Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Early trial explores new drug for blood cancers in japanese patients

NCT ID NCT05673460

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called nemtabrutinib in 7 Japanese adults with certain blood cancers (like chronic lymphocytic leukemia). The main goals were to check the drug's safety and how the body processes it. Researchers looked for side effects and measured drug levels in the blood.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

7 people

The number who actually took part.

Started

Feb 2023

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

The main inclusion and exclusion criteria include but are not limited to the following: Inclusion Criteria: * Histologically confirmed B-cell malignancy: * Chronic lymphocytic leukemia (CLL) * Small lymphocytic lymphoma (SLL) * Waldenström's macroglobulinemia (WM) * Lymphoplasmacytic lymphoma (LPL) * Other B-cell neoplasm * Failed or intolerant to either at least 2 prior regimens given in combination or sequentially OR have received 1 prior Bruton's tyrosine kinase (BTK)-containing regimen when a BTK inhibitor is approved as first line therapy * Have the ability to swallow and retain oral medication * Is Japanese Exclusion Criteria: * Active Hepatitis B virus (HBV)/Hepatitis C virus (HCV) infection at study entry * History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years * Known history of human immunodeficiency virus (HIV) infection * Clinically significant gastrointestinal abnormalities that might alter absorption (eg, gastric bypass surgery, gastrectomy) * Underlying history of severe bleeding disorders * History or concurrent condition of pneumonitis/interstitial lung disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia lymphoplasmacytic lymphoma neoplasm of mature B-cells Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mature B-cell neoplasms

Contacts and locations

Locations

  • Chiba Cancer Center ( Site 0005)

    Chiba, 260-8717, Japan

  • Kindai University Hospital ( Site 0006)

    Sayama, Osaka, 589-8511, Japan

  • Kyushu University Hospital ( Site 0008)

    Fukuoka, 812-8582, Japan

  • Nagoya University Hospital ( Site 0003)

    Nagoya, Aichi-ken, 466-8560, Japan

  • National Cancer Center Hospital East ( Site 0002)

    Kashiwa, Chiba, 2778577, Japan

  • Okayama University Hospital ( Site 0007)

    Okayama, 700-8558, Japan

  • Yamagata University Hospital ( Site 0001)

    Yamagata, 990-9585, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.